ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.

CMMB Chemomab Therapeutics Ltd

0,81
0,085 (11,72%)
10 Mai 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Chemomab Therapeutics Ltd CMMB NASDAQ Depository Receipt
  Änderung Änderung % Aktuell Zeit
0,085 11,72% 0,81 06:00:02
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
0,735 0,6921 0,85 0,81 0,725
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
09.5.202413:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
09.5.202413:00GLOBEChemomab Therapeutics Announces First Quarter 2024 Financial..
08.5.202413:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08.5.202413:00GLOBEChemomab Therapeutics Granted 180-Day Extension by Nasdaq to..
02.5.202413:00GLOBEChemomab Therapeutics to Present at 2024 Aegis Virtual..
24.4.202413:00GLOBEChemomab Therapeutics to Report First Quarter 2024 Financial..
18.4.202413:00GLOBEChemomab Reports New Peer-Reviewed Publication Reinforcing..
02.4.202413:00GLOBEChemomab to Host Virtual Key Opinion Leader Webinar on..
25.3.202412:06GLOBEChemomab Awarded New European Patent for CM-101, Its..
07.3.202413:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07.3.202413:00PRNUSChemomab Therapeutics Announces Year End and Fourth Quarter..
05.3.202413:00PRNUSChemomab Therapeutics to Participate in Leerink Global..
20.2.202415:20APSBiotech Shares Massively Bid Up Before Opening Bell
20.2.202413:00PRNUSChemomab Awarded New Patents for CM-101, Its First-in Class..
14.2.202413:00PRNUSChemomab Therapeutics to Report Fourth Quarter and Full Year..
05.2.202413:00PRNUSChemomab Therapeutics to Participate in Upcoming Investor..
30.1.202413:00PRNUSChemomab Therapeutics Announces New Publication Reinforcing..
03.1.202413:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
03.1.202413:00PRNUSChemomab Announces Completion of Patient Enrollment in..
16.11.202313:00PRNUSChemomab Presentation at ACR Convergence 2023 Provides..
15.11.202322:35EDGAR2Form SC 13D/A - General statement of acquisition of..
15.11.202313:00PRNUSChemomab Therapeutics Receives FDA Fast Track Designation..
13.11.202314:00PRNUSChemomab Presents New Clinical Data Supporting CM-101's..
09.11.202314:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
09.11.202314:00PRNUSChemomab Therapeutics Announces Third Quarter 2023 Financial..
06.11.202322:15PRNUSChemomab Therapeutics Discloses Receipt of Nasdaq Notice..
06.11.202306:15EDGAR2Form EFFECT - Notice of Effectiveness
30.10.202313:33EDGAR2Form F-3/A - Registration statement by foreign private..
30.10.202312:00PRNUSChemomab Therapeutics to Report Third Quarter 2023 Financial..
26.10.202313:00PRNUSChemomab Therapeutics to Present at Upcoming Scientific..
16.10.202322:25EDGAR2Form F-3 - Registration statement by foreign private issuers
28.9.202313:00PRNUSChemomab Therapeutics to Present Its CM-101 Clinical Program..
29.8.202313:00PRNUSChemomab Therapeutics to Present at the H.C. Wainwright 25th..
14.8.202314:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14.8.202314:00PRNUSChemomab Therapeutics Announces Second Quarter 2023..
08.8.202312:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05.7.202323:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03.7.202321:49EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
28.6.202313:00PRNUSChemomab Therapeutics Announces Publication in JCI Insight..
26.6.202313:00PRNUSChemomab Therapeutics Presents Data Reinforcing the Clinical..
21.6.202313:00PRNUSChemomab Therapeutics Reports Positive Data from Secondary..
05.6.202313:00PRNUSChemomab Therapeutics Announces Executive Leadership Changes..
02.6.202315:00PRNUSPatient Data Presented at 2023 EULAR Congress Highlights How..
24.5.202313:00PRNUSChemomab Therapeutics to Participate in Upcoming Scientific..
11.5.202312:00PRNUSChemomab Therapeutics Announces First Quarter 2023 Financial..

Kürzlich von Ihnen besucht

Delayed Upgrade Clock